SEC Comment Letter 0000000000-24-013367 to CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CERO THERAPEUTICS HOLDINGS, INC.
Date: Dec. 4, 2024 · CIK: 0001870404 · Accession: 0000000000-24-013367
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283492
Letter
December 4, 2024 Andrew Kucharchuk Chief Financial Officer CERo Therapeutics Holdings, Inc. 201 Haskins Way, Suite 230 South San Francisco, CA 94080 Re:CERo Therapeutics Holdings, Inc. Registration Statement on Form S-1 Filed November 27, 2024 File No. 333-283492 Dear Andrew Kucharchuk: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jeffrey A Letalien, Esq.
Show Raw Text
December 4, 2024
Andrew Kucharchuk
Chief Financial Officer
CERo Therapeutics Holdings, Inc.
201 Haskins Way, Suite 230
South San Francisco, CA 94080
Re:CERo Therapeutics Holdings, Inc.
Registration Statement on Form S-1
Filed November 27, 2024
File No. 333-283492
Dear Andrew Kucharchuk:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jeffrey A Letalien, Esq.